No Data
No Data
Unusual Options Activity: WFC, SNAP and Others Attract Market Bets, WFC V/OI Ratio Reaches 156.8
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $60 From $57
Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase
Express News | Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Bristol-Myers Squibb Analyst Ratings
103811615 : Nyi Nyi Htwe Y324412